Payment overview · 2025
General Payments
$185.09
8 reported records · 7 companies
Healthcare provider profile · identity verified
Felix Alejandro Ramirez Labrada, M.D
Allopathic & Osteopathic Physicians|Family Medicine · MIAMI LAKES, FL · NPI 1356696652
Verified facts
What the public records show
CMS Open Payments records show Felix Alejandro Ramirez Labrada, M.D received $185.09 in general payments during 2025 across 8 reported records.
PFIZER INC. accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.94 | 22.7% | 2 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $38.75 | 20.9% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $23.67 | 12.8% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $21.86 | 11.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.99 | 11.3% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $20.07 | 10.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.81 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $185.09 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $38.75 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 556 | 223 |
| Metformin Hcl | Metformin Hcl | 450 | 169 |
| Losartan Potassium | Losartan Potassium | 349 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 339 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 332 | 118 |
| Gabapentin | Gabapentin | 306 | 140 |
| Lisinopril | Lisinopril | 294 | 115 |
| Omeprazole | Omeprazole | 262 | 101 |
| Hydrochlorothiazide | Hydrochlorothiazide | 255 | 102 |
| Azithromycin | Azithromycin | 253 | 180 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 223 | 78 |
| Trazodone Hcl | Trazodone Hcl | 162 | 72 |
| Fluticasone Propionate | Fluticasone Propionate | 159 | 82 |
| Montelukast Sodium | Montelukast Sodium | 159 | 65 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 158 | 111 |
| Famotidine | Famotidine | 153 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 59 |
| Methylprednisolone | Methylprednisolone | 147 | 109 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 45 |
| Ibuprofen | Ibuprofen | 122 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 61 |
| Methocarbamol | Methocarbamol | 107 | 78 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 104 | 71 |
| Glipizide | Glipizide | 97 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 32 |
| Alprazolam | Alprazolam | 91 | 17 |
| Valsartan | Valsartan | 89 | 29 |
| Mupirocin | Mupirocin | 88 | 60 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 80 | 67 |
| Sertraline Hcl | Sertraline Hcl | 78 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 51 |
| Atenolol | Atenolol | 72 | 24 |
| Furosemide | Furosemide | 71 | 28 |
| Temazepam | Temazepam | 71 | 12 |
| Simvastatin | Simvastatin | 70 | 24 |
| Meloxicam | Meloxicam | 65 | 27 |
| Mirtazapine | Mirtazapine | 65 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 53 |
| Eliquis | Apixaban | 63 | 19 |
| Carvedilol | Carvedilol | 61 | 24 |
| Chlorthalidone | Chlorthalidone | 57 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 45 |
| Celecoxib | Celecoxib | 51 | 17 |
| Clonazepam | Clonazepam | 47 | 13 |
| Naproxen | Naproxen | 46 | 34 |
| Levofloxacin | Levofloxacin | 45 | 43 |
| Meclizine Hcl | Meclizine Hcl | 44 | 30 |
| Synthroid | Levothyroxine Sodium | 44 | 13 |
| Donepezil Hcl | Donepezil Hcl | 43 | 17 |
| Ketoconazole | Ketoconazole | 43 | 30 |
| Mometasone Furoate | Mometasone Furoate | 42 | 26 |
| Prednisone | Prednisone | 42 | 31 |
| Baclofen | Baclofen | 40 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 40 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 35 |
| Alendronate Sodium | Alendronate Sodium | 38 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Ciclopirox | Ciclopirox | 37 | 19 |
| Fluconazole | Fluconazole | 36 | 31 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 13 |
| Ondansetron Odt | Ondansetron | 33 | 25 |
| Enalapril Maleate | Enalapril Maleate | 31 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Dexamethasone | Dexamethasone | 27 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 18 |
| Lorazepam | Lorazepam | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | 11 |
| Metronidazole | Metronidazole | 27 | 26 |
| Allopurinol | Allopurinol | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 23 | 14 |
| Cefuroxime | Cefuroxime Axetil | 23 | 21 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 11 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Ofloxacin | Ofloxacin | 22 | 19 |
| Spironolactone | Spironolactone | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | 12 |
| Folic Acid | Folic Acid | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 12 |
| Nystatin | Nystatin | 21 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Clotrimazole | Clotrimazole | 18 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 18 | 17 |
| Sucralfate | Sucralfate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Erythromycin | Erythromycin Base | 15 | 13 |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $185.09 · 8 records | PFIZER INC. | APTIMA, Evoke, FARXIGA, Flector, Licart, NURTEC ODT, PAXLOVID, THINPREP 2000 PROCESSOR, Tirosint, Xhance, ZAVZPRET, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error